JNJ-78934804 vs SPY003

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

SPY003

Developed by Spyre Therapeutics

Phase 2 in Ulcerative Colitismonoclonal antibody (anti-IL-23)
Partial signal

NCT07012395 · Phase 2 · recruiting

This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: June 2027 · NCT07012395 (registry estimate)

Reported efficacy

Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)

Result source: NCT07012395

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804SPY003
Clinical remission (induction)—Trial running · NCT07577856—Not reported
Clinical remission (maintenance)—Trial running · NCT07577856—Not reported
Clinical response (induction)—Trial running · NCT07577856—Not reported
Endoscopic improvement (induction)—Trial running · NCT07577856—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT07577856—Not reported

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577856
SPY003
—Not reported

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
SPY003
—Not reported

Clinical response (induction)

JNJ-78934804
—Trial running · NCT07577856
SPY003
—Not reported

Endoscopic improvement (induction)

JNJ-78934804
—Trial running · NCT07577856
SPY003
—Not reported

Corticosteroid-free remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
SPY003
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SPY003
Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). NCT07012395 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · SPY003's landscape